ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Mar 14, 2023 11:09 JST
Source:
Eisai
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
Eisai is Proud to Support U.S. Veterans Living With Early Stages of Alzheimer's Disease and Will Continue to Transparently Share our High-Quality Data with the VHA
TOKYO, Mar 14, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that the U.S. Veterans' Health Administration (VHA) is providing coverage of LEQEMBI (lecanemab-irmb) to veterans living with early stages of Alzheimer's disease (AD). VHA healthcare professionals meeting the criteria set forth by the VHA can prescribe LEQEMBI to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. The VHA's careful consideration and timely action to make LEQEMBI available approximately two months after the FDA approved LEQEMBI under the accelerated approval pathway shows its continued commitment to veterans living with AD.
If approved under the traditional pathway, the FDA will update the label for LEQEMBI, which will include new data that has been evaluated by the FDA. Eisai looks forward to sharing additional high-quality data as it becomes available and to continuing discussions with the VHA as the company prepares for the FDA's potential conversion of LEQEMBI's accelerated approval to a traditional approval. Eisai is proud of and humbled by the opportunity to support U.S. veterans as we strive to fulfill our human health care (hhc) mission.
LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibrils*) and insoluble forms of amyloid beta (Aβ), LEQEMBI was approved in the U.S. under the Accelerated approval Pathway for the treatment of AD on January 6, 2023, and was launched in the U.S on January 18, 2023. Treatment with LEQEMBI should only be initiated in patients with mild cognitive impairment or mild dementia stage of disease and confirmed presence of Aβ pathology.
The Accelerated approval was based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of AD, and its continued approval may be contingent upon verification of LEQEMBI's clinical benefit in a confirmatory trial. The FDA has determined that the results of Clarity AD will serve as the confirmatory study to verify the clinical benefit of LEQEMBI.
On the same day that LEQEMBI received its Accelerated approval, Eisai submitted the supplemental Biologics License Application (sBLA) to the FDA for approval under the Traditional pathway. The sBLA was accepted by the FDA on March 3, 2023 and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) date of July 6, 2023. The sBLA is based on the findings from Eisai's recently published large, global confirmatory Phase 3 clinical trial, Clarity AD. LEQEMBI met the primary endpoint and all key secondary endpoints with highly statistically significant results. In November 2022, results of the Clarity AD study were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference and simultaneously published in the peer-reviewed medical journal, The New England Journal of Medicine.
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
*Protofibrils are large Aβ aggregated soluble species of 75-500 Kd.1
To learn more, visit www.leqembi.com/, www.eisai.com/news/2023/news202319.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Eisai Inc (U.S.)
Libby Holman
201-753-1945
Libby_Holman@eisai.com
Eisai Europe, Ltd.
(UK, Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44-(0)-786-601-1272
EMEA-comms@eisai.net
Source: Eisai
Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
DOCOMO and NTT Com Jointly Demonstrate Practicality of DOCOMO's New Multi-platform Cloud-rendering Technology
Jul 26, 2024 17:05 JST
TANAKA Precious Metals Provided Award Items and Ceremony Souvenirs for the International Friendly Matches of the Japan Men's National Blind Football Team at the "DAICEL Blind Football Japan Cup 2024 in Osaka" on July 7
Jul 26, 2024 03:00 JST
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
Jul 25, 2024 10:30 JST
Hitachi Awarded Largest Contract in Singapore to Supply 450 Lifts at HDB Blocks
Jul 24, 2024 16:27 JST
Hitachi to Announce Capital Reorganization of Air Conditioning Joint Venture
Jul 24, 2024 15:02 JST
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
Jul 23, 2024 20:23 JST
Toyota Material Handling Japan and Fujitsu launch Japan's first service for evaluating forklift safety in the cloud using AI
Jul 23, 2024 11:26 JST
AEON and CJPT working to resolve logistics industry issues and achieve carbon neutrality at AEON Fukuoka XD
Jul 22, 2024 13:52 JST
Rovanpera and Ogier score another TOYOTA GAZOO Racing one-two
Jul 22, 2024 12:30 JST
Team HRC with Japan Post Wins 45th Suzuka 8 Hours Endurance Road Race
Jul 22, 2024 11:33 JST
Honda to Hold its Official e-Motorsports Event, "Honda Racing eMS 2024"
Jul 19, 2024 20:04 JST
MHI America Acquires Three Utility-Scale Solar Power Projects in Pennsylvania, Advancing the Company's Energy Transition Strategy
Jul 19, 2024 19:04 JST
JCB and Worldline unveil a new whitepaper offering European merchants invaluable insights into facilitating seamless payments for international consumers
Jul 19, 2024 12:00 JST
Fujitsu Chosen to Help Solving Social Issues Caused by Fake News
Jul 19, 2024 11:30 JST
Champion REIT holds first 'ESG Week'
Jul 18, 2024 20:14 JST
Lexus LBX Adds a New High Performance Variant, the LBX "MORIZO RR"
Jul 18, 2024 17:25 JST
VitalLife and Bumrungrad International Hospital in Thailand Launch NEC's FonesVisuas Test: First Major Deployment Outside Japan, Revolutionizing Disease Risk Prediction
Jul 18, 2024 15:34 JST
Fujitsu publishes CHRO Roundtable Report 2024, summarizing the challenges and implications of the implementation of data-driven human capital management
Jul 18, 2024 10:44 JST
Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship
Jul 16, 2024 23:26 JST
Neste and Mitsubishi Corporation agree on strategic partnership to develop supply chains for renewable chemicals and plastics
Jul 16, 2024 18:36 JST
More Latest Release >>
Related Release
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
7/25/2024 10:30:00 AM JST
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
7/23/2024 8:23:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
7/12/2024 12:56:00 PM JST
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
7/11/2024 10:00:00 AM JST
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
7/2/2024 1:01:00 PM JST
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
6/28/2024 3:57:00 PM JST
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
6/21/2024 3:35:00 PM JST
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
6/10/2024 6:50:00 PM JST
Eisai Named to List of The Time 100 Most Influential Companies
6/3/2024 5:08:00 PM JST
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
6/3/2024 3:22:00 PM JST
More Press release >>